Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

Journal of Clinical Investigation

Volumn 103, Issue 12, 1999, Pages 1635-1640

  Ono Nita, Suzane Kioko ^a   Kato, Naoya ^a   Shiratori, Yasushi ^a   Lan, Keng Hsin ^a   Yoshida, Hideo ^a   Carrilho, Flair José ^b   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; LAMIVUDINE; LOBUCAVIR; NEVIRAPINE; PENCICLOVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0032693145     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5882     Document Type: Article

References (51)

1. World Health Organization warns of growing "crisis of suffering." 1997. http://www.who.ch/whr/1997/presse.htm.
2. Wong, D.K.H., et al. 1993. Effect of alpha-interferon treatment in patients with hepatitis B antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119:312-323.
3. Summers, J., and Mason, W.S. 1982. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell. 29:403-415.
4. Dienstag, J.L., et al. 1995. A preliminary trial of lamivudine for chronic hepatitis B virus infection. N. Engl. J. Med. 333:1657-1661.
5. Honkoop, P., de Man, R.A., Zondervan, P.E., and Schalm, S.W. 1997. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver. 17:103-106.
6. Lai, C.L., et al. 1997. Genotypic resistance to lamivudine in a prospective placebo-controlled multicenter study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence kinetics of emergence and correlation with disease parameters. Hepatology. 26:259A. (Abstr.)
7. Honkoop, P., Niesters, H.G.M., de Man, R.A.M., Osterhaus, A.D.M.E., and Schalm S.W. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B.J. Hepatol. 26:1393-1395.
8. Lai, C. L., et al. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
9. Tipples, G.A., et al. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatolagy. 24:714-717.
10. Bartholomew, M.M., et al. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:20-22.
11. Ling, R., et al. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:711-713.
12. Kamer, G., and Argos, P. 1984. Primary structural comparison of RNA-dependent polymerases from plant, animal and bacterial viruses. Nucleic Acids Res. 12:7269-7282.
13. De Castro, L.M., et al. 1991. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res. 16:101-114.
14. Balzarini, J., et al. 1989. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyerhyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl. Acad. Sci. USA. 86:332-336.
15. Decks, S.G., et al. 1997. The safety and efficacy of adefovir-dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 176:1517-1523.
16. Gilson, R.J.C., et al. 1996. A placebo-controlled phase I/II study of adefovir dipovoxil (bis-POM PMEA) in patients with chronic hepatitis B infection. Hepatology. 24:281A. (Abstr.)
17. Jeffers, L., et al. 1998. A phase II dose-ranging, placebo-controled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection. Antiviral Res. 37:A197. (Abstr.)
18. Terry, B.J., Cianci, C.W., and Hagen, M.E. 1991. Inhibition of herpes simplex virus type I DNA polymerase by [1R(1α,2β,3α)]-9-[2,3-Bis(hydroxymethyl)cyclobutyl] guanine. Mol. Pharmacol. 40:591-596.
19. Yang, H., Drain, R.L., Franco, C.A., and Clark, J.M. 1996. Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice. Antiviral Res. 26:1-9.
20. Flaherty, J.F., Jr. 1996. Current and experimental therapeutic options for cytomegalovirus disease. Am. J. Health Syst. Pharm. 53(Suppl. 2):S4-S11.
21. Innaimo, S.F., et al. 1997. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41:1444-1448.
22. Bloomer, J., Chan, R., Sherman, M., and Ingraham, P. 1997. Phase 1/2 study of oral Lobucavir in adults with chronic hepatitis B infection. In Program and abstracts of the Second International Conference on Therapies for Viral Hepatitis. Kona, HI. 23. (Abstr.)
23. Boyd, M.R., Safrin, S., and Kern, E.R. 1993. Penciclovir: a review of its spectrum of activity, selectivity and cross-resistance pattern. Antiviral Chem. Chemother. 4(Suppl. 1):3-11.
24. Bacon, T.H. 1996. Famciclovir, from the bench to the patient: a comprehensive review of preclinical data. Int. J. Antimicrob. Agents. 7:119-134.
25. Shaw, T., Mok, S.S., and Locarnini, S.A. 1996. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 24:996-1002.
26. Korba, B.H., and Boyd, M.R. 1996. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemother. 40:1282-1284.
27. Colledge, D., Locarnini, S., and Shaw, T. 1997. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 26:216-225.
28. Korba, B.E. 1995. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res. 29:49-51.
29. Lin, E., Luscombe, C., Colledge, D., Wang, Y.Y., and Locarnini, S. 1998. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 42:2132-2137.
30. Böker, K.H.W., Ringe, B., Krüger, M., Pichmayr, R., and Manss MP. 1994. Prostaglandin E plus famciclovir: a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation. 54:1706-1708.
31. Klein, M., et al. 1997. Conversion of recurrent delta-positive hepatitis B infection to seronegarivity with famciclovir after liver transplantation. Transplantation. 64:162-163.
32. Aye, T.T., et al. 1997. Hepatitis B polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol. 26:1148-1153.
33. Singh, N., Gayowski, T., Wannstedt, C. F., Wagener, M.M., and Marino, I.R. 1997. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation. 63:1415-1419.
34. Spence, R.A., Kati, W.M., Anderson, K.S., and Johnson, A.K. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:988-993.
35. Kupec, I.F. 1996. FDA approves nevirapine to treat HIV, http://www.fda.gov/bbs/topics/ANSWERS/ANS00742.html.
36. Ono-Nita, S.K., et al. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology. 29:939-945.
37. Allen, M.I., et al. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 27:1670-1677.
38. Togo, G., et al. 1996. A transforming growth factor b type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res. 56:5620-5623.
39. Günther, S., et al. 1995. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J. Virol. 69:5437-5444.
40. Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T., and Sato J. 1982. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res. 42:3858-3863.
41. Fischer, K.P., and Tyrrel, D.L.J. 1996. Generation of duck hepatitis B virus polymerase mutants through site-directed inutagenesis which demonstrate resistance to lamivudine [(-)-βL-2′, 3′-dideoxi-3′-thiacytidine] in vitro. Antimicrob. Agents Chemother. 40:1957-1960.
42. Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 16.56-16.67.
43. Yokosuka O., Omata, M., Imazeki, F., Okuda, K., and Summers, J. 1985. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology. 5:728-734.
44. Korba, B.E., and Germ, J.L. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19:55-70.
45. Yokota, T., et al. 1991. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob. Agents Chemother 35:394-397.
46. Heitjink, R.A., et al. 1993. Inhibitory effect of 9-(phosphonyl-methoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 21:141-153.
47. DeHertogh, D., Collono, R., and Grasela, D. 1997. Lobucavir and BMS-200475: two potent new agents for hepatitis B. In Program and abstracts of the Second International Conference on Therapies for Viral Hepatitis. Kona, HI. 1. (Abstr.)
48. Cherrington, J.M., Mulato, A.S., Fuller, M.D., and Chen, M.S. 1996. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxyl)ethyl]adenine in vitro. Antimicrob. Agents Chemother. 40:2212-2216.
49. Lau, G.K., et al. 1999. Treatment of chronic hepatitis B virus infection: an Asian-Pacific perspective. J. Gastroenterol. Hepatol. 14:3-12.
50. Hong, J.H., Choi, Y., Chun, B.K., Lee, K., and Chu, C.K. 1998. Current status of anti-HBV chemotherapy. Arch. Pharm. Res. 21:89-105.
51. Omata, M. 1998. Treatment of chronic hepatitis B infection. N. Engl. J. Med. 339:114-115.